We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-7.00 | -0.44% | 1,576.50 | 1,576.00 | 1,576.50 | 1,583.50 | 1,575.50 | 1,579.50 | 242,237 | 09:45:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.20 | 65.05B |
TIDMGSK
RNS Number : 6484D
GlaxoSmithKline PLC
20 February 2020
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') === ====================================================================================== a) Name Ms E Walmsley === ================================ ==================================================== b) Position/status Chief Executive Officer === ================================ ==================================================== c) Initial notification/ Initial notification amendment === ================================ ==================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================================== a) Name GlaxoSmithKline plc === ================================ ==================================================== b) LEI 5493000HZTVUYLO1D793 === ================================ ==================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ==================================================== b) Nature of the The exercise of nil-cost options over Ordinary transaction Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ==================================================== c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ ============================== GBP0.00 37,221 (Deferred) === ================================ ================ ============================== GBP0.00 24,815 (Matching) ================ ============================== d) Aggregated information N/A (single transaction) === Aggregated volume 62,036 Price GBP0.00 === ================================ ==================================================== e) Date of the transaction 2020-02-17 === ================================ ==================================================== f) Place of the N/A transaction === ================================ ==================================================== 1. Details of PDMR/person closely associated with them ('PCA') === ==================================================================================== a) Name Ms E Walmsley === ================================ ================================================== b) Position/status Chief Executive Officer === ================================ ================================================== c) Initial notification/ Initial notification amendment === ================================ ================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ==================================================================================== a) Name GlaxoSmithKline plc === ================================ ================================================== b) LEI 5493000HZTVUYLO1D793 === ================================ ================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ==================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ================================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities on the exercise of nil-cost options under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ================================================== c) Price(s) and Price(s) Volume(s) volume(s) === ================================ =============== ============================= GBP16.614 17,523 (Deferred) === ================================ =============== ============================= GBP16.614 11,680 (Matching) =============== ============================= d) Aggregated information N/A (single transaction) === Aggregated volume 29,203 Price GBP16.614 === ================================ ================================================== e) Date of the transaction 2020-02-17 === ================================ ================================================== f) Place of the London Stock Exchange (XLON) transaction === ================================ ================================================== 1. Details of PDMR/person closely associated with them ('PCA') === ====================================================================================== a) Name Mr R Connor === ================================ ==================================================== b) Position/status President, Global Vaccines === ================================ ==================================================== c) Initial notification/ Initial notification amendment === ================================ ==================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================================== a) Name GlaxoSmithKline plc === ================================ ==================================================== b) LEI 5493000HZTVUYLO1D793 === ================================ ==================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ==================================================== b) Nature of the The exercise of nil-cost options over Ordinary transaction Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ==================================================== c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ ============================== GBP0.00 19,375 (Deferred) === ================================ ================ ============================== GBP0.00 12,917 (Matching) ================ ============================== d) Aggregated information N/A (single transaction) === Aggregated volume 32,292 Price GBP0.00 === ================================ ==================================================== e) Date of the transaction 2020-02-17 === ================================ ==================================================== f) Place of the N/A transaction === ================================ ==================================================== 1. Details of PDMR/person closely associated with them ('PCA')
=== =================================================================================== a) Name Mr R Connor === ================================ ================================================= b) Position/status President, Global Vaccines === ================================ ================================================= c) Initial notification/ Initial notification amendment === ================================ ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =================================================================================== a) Name GlaxoSmithKline plc === ================================ ================================================= b) LEI 5493000HZTVUYLO1D793 === ================================ ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ================================================= b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ================================================= c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ =========================== GBP16.714 9,120 (Deferred) === ================================ ================ =========================== GBP16.714 6,081 (Matching) ================ =========================== d) Aggregated information === Aggregated volume 15,201 Price GBP16.714 === ================================ ================================================= e) Date of the transaction 2020-02-17 === ================================ ================================================= f) Place of the London Stock Exchange (XLON) transaction === ================================ ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === ====================================================================================== a) Name Mr N Hirons === ================================ ==================================================== b) Position/status SVP, Global Ethics and Compliance === ================================ ==================================================== c) Initial notification/ Initial notification amendment === ================================ ==================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================================== a) Name GlaxoSmithKline plc === ================================ ==================================================== b) LEI 5493000HZTVUYLO1D793 === ================================ ==================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ==================================================== b) Nature of the The exercise of nil-cost options over Ordinary transaction Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ==================================================== c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ ============================== GBP0.00 12,243 (Deferred) === ================================ ================ ============================== GBP0.00 8,163 (Matching) ================ ============================== d) Aggregated information N/A (single transaction) === Aggregated volume 20,406 Price GBP0.00 === ================================ ==================================================== e) Date of the transaction 2020-02-17 === ================================ ==================================================== f) Place of the N/A transaction === ================================ ==================================================== 1. Details of PDMR/person closely associated with them ('PCA') === =================================================================================== a) Name Mr N Hirons === ================================ ================================================= b) Position/status SVP, Global Ethics and Compliance === ================================ ================================================= c) Initial notification/ Initial notification amendment === ================================ ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =================================================================================== a) Name GlaxoSmithKline plc === ================================ ================================================= b) LEI 5493000HZTVUYLO1D793 === ================================ ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ================================================= b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ================================================= c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ =========================== GBP16.678 5,770 (Deferred) === ================================ ================ =========================== GBP16.678 3,846 (Matching) ================ =========================== d) Aggregated information === Aggregated volume 9,616 Price GBP16.678 === ================================ ================================================= e) Date of the transaction 2020-02-17 === ================================ ================================================= f) Place of the London Stock Exchange (XLON) transaction === ================================ ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== ===================================================================================== a) Name Mr B McNamara ==== ================================== =================================================
b) Position/status CEO, GSK Consumer Healthcare ==== ================================== ================================================= c) Initial notification/ Initial notification amendment ==== ================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ===================================================================================== a) Name GlaxoSmithKline plc ==== ================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ===================================================================================== a) Description of American Depositary Shares ('ADSs') the financial instrument ISIN: US37733W1053 ==== ================================== ================================================= b) Nature of the The sale of ADSs to meet tax liabilities transaction on the vesting of awards under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. ==== ================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ================================== ================ ============================= $43.544 3,467 (Deferred) ==== ================================== ================ ============================= $43.544 2,423 (Matching) ================ ============================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price 5,890 $43.544 ======================================= ================================================= e) Date of the transaction 2020-02-18 ==== ================================== ================================================= f) Place of the New York Stock Exchange (XNYS) transaction ==== ================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === ====================================================================================== a) Name Mr D Redfern === ================================ ==================================================== b) Position/status Chief Strategy Officer === ================================ ==================================================== c) Initial notification/ Initial notification amendment === ================================ ==================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ====================================================================================== a) Name GlaxoSmithKline plc === ================================ ==================================================== b) LEI 5493000HZTVUYLO1D793 === ================================ ==================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ====================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ==================================================== b) Nature of the The exercise of nil-cost options over Ordinary transaction Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ==================================================== c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ ============================== GBP0.00 15,407 (Deferred) === ================================ ================ ============================== GBP0.00 10,273 (Matching) ================ ============================== d) Aggregated information === Aggregated volume 25,680 Price GBP0.00 === ================================ ==================================================== e) Date of the transaction 2020-02-17 === ================================ ==================================================== f) Place of the N/A transaction === ================================ ==================================================== 1. Details of PDMR/person closely associated with them ('PCA') === =================================================================================== a) Name Mr D Redfern === ================================ ================================================= b) Position/status Chief Strategy Officer === ================================ ================================================= c) Initial notification/ Initial notification amendment === ================================ ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =================================================================================== a) Name GlaxoSmithKline plc === ================================ ================================================= b) LEI 5493000HZTVUYLO1D793 === ================================ ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ================================================= b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ================================================= c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ =========================== GBP16.629 7,261 (Deferred) === ================================ ================ =========================== GBP16.629 4,840 (Matching) ================ =========================== d) Aggregated information N/A (single transaction) === Aggregated volume 12,101 Price GBP16.629 === ================================ ================================================= e) Date of the transaction 2020-02-17 === ================================ ================================================= f) Place of the London Stock Exchange (XLON) transaction === ================================ ================================================= 1. Details of PDMR/person closely associated with them ('PCA') === ======================================================================================= a) Name Mr P Thomson === ================================= ==================================================== b) Position/status President, Global Affairs === ================================= ==================================================== c) Initial notification/ Initial notification
amendment === ================================= ==================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ======================================================================================= a) Name GlaxoSmithKline plc === ================================= ==================================================== b) LEI 5493000HZTVUYLO1D793 === ================================= ==================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ======================================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================= ==================================================== b) Nature of the The exercise of nil-cost options over Ordinary transaction Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================= ==================================================== c) Price(s) and Price(s) Volume(s) volume(s) === ================================= ================ ============================== GBP0.00 7,302 (Deferred) === ================================= ================ ============================== GBP0.00 4,869 (Matching) ================ ============================== d) Aggregated information === Aggregated volume 12,171 Price GBP0.00 === ================================= ==================================================== e) Date of the transaction 2020-02-17 === ================================= ==================================================== f) Place of the N/A transaction === ================================= ==================================================== 1. Details of PDMR/person closely associated with them ('PCA') === =================================================================================== a) Name Mr P Thomson === ================================ ================================================= b) Position/status President, Global Affairs === ================================ ================================================= c) Initial notification/ Initial notification amendment === ================================ ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === =================================================================================== a) Name GlaxoSmithKline plc === ================================ ================================================= b) LEI 5493000HZTVUYLO1D793 === ================================ ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === =================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ================================ ================================================= b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. === ================================ ================================================= c) Price(s) and Price(s) Volume(s) volume(s) === ================================ ================ =========================== GBP16.623 3,442 (Deferred) === ================================ ================ =========================== GBP16.623 2,294 (Matching) ================ =========================== d) Aggregated information N/A (single transaction) === Aggregated volume 5,736 Price GBP16.623 === ================================ ================================================= e) Date of the transaction 2020-02-17 === ================================ ================================================= f) Place of the London Stock Exchange (XLON) transaction === ================================ =================================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHXBLFLBLLEBBQ
(END) Dow Jones Newswires
February 20, 2020 09:00 ET (14:00 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions